SCHEMBL14330600

SCHEMBL14330600

c1ccc(-n2c3cnccc3c3c4ccc5ccc(-c6cccc(-c7ccncc7)n6)c6ccc(cc32)c4c56)cc1

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ DYRK1A Q13627 4/20 0.39
▸ KCNH2 Q12809 6/20 0.34
▸ GSK3B P49841 2/20 0.34
▸ CDK4 P11802 3/20 0.33
▸ CDK6 Q00534 3/20 0.33
▸ MAPT P10636 2/20 0.33
▸ KDM4E B2RXH2 1/20 0.33
▸ ALDH1A1 P00352 1/20 0.33
▸ HPGD P15428 1/20 0.33
▸ MAPK1 P28482 1/20 0.32
▸ AOC3 Q16853 3/20 0.31
▸ REN P00797 2/20 0.30
▸ NFATC1 O95644 1/20 0.30
▸ PRKCB P05771 1/20 0.30
▸ PRKCA P17252 1/20 0.30
▸ PRKCH P24723 1/20 0.30
▸ PRKCE Q02156 1/20 0.30
▸ PRKCQ Q04759 1/20 0.30
▸ PRKCD Q05655 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14330564 0.92 DYRK1A (0.34) DYRK1AKCNH2GSK3BMAPTKDM4E
SCHEMBL14330520 0.84 TLR5 (0.32) MAPTKDM4EALDH1A1HPGDMAPK1
SCHEMBL14330589 0.83 DYRK1A (0.37) DYRK1AKCNH2GSK3BCDK4CDK6
SCHEMBL14330599 0.81 MAPT (0.34) DYRK1AKCNH2GSK3BMAPTKDM4E
SCHEMBL14330584 0.81 CDK4 (0.34) DYRK1AKCNH2GSK3BCDK4CDK6
SCHEMBL14330572 0.81 CYP11B1 (0.37) DYRK1AKCNH2GSK3BCDK4CDK6
SCHEMBL14330593 0.80 DYRK1A (0.37) DYRK1AKCNH2GSK3BCDK4CDK6
SCHEMBL14330588 0.80 KDM4E (0.36) DYRK1AKCNH2GSK3BCDK4CDK6
SCHEMBL14329625 0.79 CDK4 (0.39) DYRK1AKCNH2GSK3BCDK4CDK6
SCHEMBL14330623 0.79 CDK4 (0.37) DYRK1AKCNH2GSK3BCDK4CDK6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8623521-B2 Heterocyclic compound and organic light-emitting diode and flat display device including the heterocyclic compound SAMSUNG DISPLAY CO., LTD. (KR) 2014-01-07 — — US disclosed
US-8623521-B2 Heterocyclic compound and organic light-emitting diode and flat display device including the heterocyclic compound SAMSUNG DISPLAY CO., LTD. (KR) 2014-01-07 — — US disclosed
US-20120326134-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DIODE AND FLAT DISPLAY DEVICE INCLUDING THE HETEROCYCLIC COMPOUND SAMSUNG DISPLAY CO., LTD. (KR) 2012-12-27 — — US disclosed
US-20120326134-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DIODE AND FLAT DISPLAY DEVICE INCLUDING THE HETEROCYCLIC COMPOUND SAMSUNG DISPLAY CO., LTD. (KR) 2012-12-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120326134-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DIODE AND FLAT DISPLAY DEVICE INCLUDING THE HETEROCYCLIC COMPOUND DDT, DRD1, HTR3D DYRK1A 3897/4885KCNH2 2141/4885GSK3B 3143/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback